Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Thermally-Activated Delayed Fluorescence Nanoparticle Assemblies for Photodynamic Therapy

Descrizione del progetto

Un trattamento oncologico di precisione

La terapia fotodinamica (PDT, photodynamic therapy) è un trattamento oncologico minimamente invasivo che combina la luce di un laser con coloranti fotosensibilizzanti per uccidere le cellule tumorali: le reazioni fotochimiche, infatti, portano alla generazione di specie reattive dell’ossigeno che causano l’apoptosi delle cellule tumorali. Nonostante sia un trattamento promettente, questa terapia ha registrato progressi limitati, in quanto solo pochi coloranti sono stati approvati per l’uso clinico. Con il sostegno del programma di azioni Marie Skłodowska-Curie, il progetto TADF-PDT introdurrà una nuova classe di coloranti basati sulla fluorescenza ritardata attivata termicamente (TADF, thermally-activated delayed fluorescence). Questi materiali TADF efficienti saranno veicolati tramite vescicole extracellulari biocompatibili, offrendo una strategia di nuova generazione per garantire un trattamento del cancro più sicuro e mirato.

Obiettivo

Photodynamic Therapy (PDT) is a non-invasive cancer treatment that uses light-activated, photosensitising dyes to generate highly reactive oxygen species (ROS) within a localised biological environment, leading to the destruction of cancer cells, while sparing surrounding healthy tissue. The PDT process comprises two stages: administration of a dye, followed by irradiation with light. Since ROS is only generated at the light-activated sites, tissue destruction is highly localised and side effects are significantly reduced. The potential for PDT is clear. However, for all this potential, widespread adoption has stagnated: only three dyes have been approved for cancer treatment globally, while the dye most commonly studied in clinical trials - Photofrin - is a statistical mixture of oligomeric porphyrins. Dye design for many years has focussed on porphyrins derived from Photofrin, and more recently phosphorescent ruthenium(II) polypyridyl complexes. However, in this proposal, a new design strategy is proposed: thermally-activated delayed fluorescence (TADF) dyes are the targets of interest. These are all-organic compounds that have small singlet-triplet energy gaps, which causes them to undergo rapid intersystem crossing and reverse intersystem crossing between the singlet and triplet states. By accessing the triplet state, they can readily generate singlet oxygen, which is one form of ROS, marking their potential for PDT. These compounds have been widely used organic device applications, but their uses in biological applications such as imaging and particularly PDT are much less. This proposal addresses this gap, using novel, cationic, near-IR emitting, TADF dyes. Their delivery to cells will be achieved using biocompatible, Extracellular Vesicles (EVs), which have been shown to be improved PDT delivery agents over other methods.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Contributo netto dell'UE
€ 260 347,92
Indirizzo
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Regno Unito
Regione
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato